MarketMoodz
Ascendis Shares Rise on Five-Year TransCon PTH Data
Ascendis Pharma shares rose Friday after the company released five-year results from the Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism, signaling durable clinical benefit. Investors cheered durable calcium control, improved kidney metrics and high rates of independence from active vitamin D and therapeutic calcium.
Key Takeaways
- PaTH Forward enrolled 59 adults with hypoparathyroidism; 56 completed the five-year follow-up.
- 82% met a composite endpoint of normal serum calcium without active vitamin D and with ≤600 mg/day calcium supplement.
- 88% achieved normal albumin-adjusted serum calcium and 96% were independent from active vitamin D therapy.
- Mean eGFR rose by 9.4 mL/min/1.73 m² from baseline and 24‑hour urine calcium normalized within 26 weeks and stayed in range through Week 266.
- Ascendis stock was up roughly 3.6% to $223.37 at publication, reflecting cautious investor optimism.
People Involved
- No specific individuals mentioned
Entities Involved
- Ascendis Pharma A/S (ASND)Developer of TransCon PTH and sponsor of the PaTH Forward Phase 2 trial
- TransCon PTH (palopegteriparatide)Ascendis's long‑acting parathyroid hormone replacement therapy studied for hypoparathyroidism
- PaTH Forward trialPhase 2 long‑term extension trial reporting five‑year efficacy and safety outcomes
- BenzingaNews outlet reporting the results (source of the summarized facts)
MarketMoodz Analysis
Durable five‑year signals like these matter because they reduce a major unknown in biopharma: long‑term efficacy and safety. For Ascendis, high rates of biochemical control (82% composite, 88% normal albumin‑adjusted calcium) and near‑universal independence from active vitamin D (96%) make TransCon PTH a stronger clinical proposition versus therapies that require lifelong active vitamin D and high calcium doses. The reported rise in mean eGFR (+9.4 mL/min/1.73 m²) and sustained normalization of 24‑hour urine calcium also address two payer and prescriber pain points—renal outcomes and metabolic safety—potentially improving reimbursement and adoption dynamics if findings are confirmed in regulatory filings and peer‑reviewed publications.
The market reaction—about a 3.6% uptick to $223.37 at publication—signals cautious optimism rather than a full re‑rating; investors are pricing in reduced technical risk but still waiting for confirmatory data and regulatory milestones. Historically, long‑term extension results can shift investor sentiment only when supported by Phase 3 readouts, label decisions or clear commercialization pathways. Ascendis will need to translate these Phase 2 outcomes into regulatory submissions, real‑world safety data and payer agreements to materially expand valuation.
What to watch next: look for an official Ascendis press release or peer‑reviewed publication that confirms the Benzinga‑reported figures, any Phase 3 or regulatory updates (FDA/EMA filings or advisory interactions), and early commercial rollout or payer coverage news where approved. Also monitor broader biotech sentiment and competitive pipelines in hypoparathyroidism, since long‑term safety signals or a rival entrant could quickly alter the investment case. Note that the reported figures in the initial report could not be independently verified here and should be validated against Ascendis's primary disclosures.
Source: Original Article